Deutsche Bank’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.01M Sell
29,944
-2,268
-7% -$97.9K ﹤0.01% 2219
2026
Q2
$1.34M Buy
32,212
+8,043
+33% +$296K ﹤0.01% 2150
2026
Q1
$756K Buy
24,169
+2,634
+12% +$74.1K ﹤0.01% 2351
2025
Q4
$653K Buy
21,535
+15,286
+245% +$423K ﹤0.01% 2426
2025
Q3
$186K Hold
6,249
– – ﹤0.01% 3099
2025
Q2
$71.1K Sell
6,249
-253
-4% -$2.68K ﹤0.01% 3361
2025
Q1
$65.2K Buy
6,502
+4,185
+181% +$54.3K ﹤0.01% 3316
2024
Q4
$41.1K Buy
+2,317
New +$51.3K ﹤0.01% 3445

Other funds holding RAPP

Deutsche Bank's RAPP Position: Q3 2026 in Review

Deutsche Bank reduced its Rapport Therapeutics (RAPP) stake by 7% in Q3 2026, selling an estimated $97.9K and leaving 29,944 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #2219.

Deutsche Bank first reported a position in RAPP in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.34M in Q2 2026. 114 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Deutsche Bank held 29,944 shares of Rapport Therapeutics worth $1.01M as of Q3 2026.
  • Deutsche Bank sold 2,268 Rapport Therapeutics shares in Q3 2026, an estimated $97.9K.
  • Rapport Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2219 holding.
  • Deutsche Bank first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Deutsche Bank's Rapport Therapeutics position peaked at $1.34M in Q2 2026.
  • 114 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.